- Novartis said it received regulatory clearance for up to 16.5 billion Swiss francs in stock repurchases.
- The company won investor authorization for up to 10 billion francs in buybacks.
- Novartis laid out plans for the $15 billion buyback programme in late 2021.
Novartis initiates new trading line for share buybacks
Novartis said on Monday it received regulatory clearance to open a separate trading line for potentially up to 16.5 billion Swiss francs ($18.1 billion) in stock repurchases even as its ongoing $15 billion buyback programme is close to completion.
/cloudfront-us-east-2.images.arcpublishing.com/reuters/P23IVAPUQNLQVIQXRXEIPOU6ZA.jpg)
/cloudfront-us-east-2.images.arcpublishing.com/reuters/RCWZE2OK3BNCJNRVFOS74NYF7M.jpg)
/cloudfront-us-east-2.images.arcpublishing.com/reuters/6W5WJY7T4NLKVFJO5JX37LPYS4.jpg)
/cloudfront-us-east-2.images.arcpublishing.com/reuters/BYL7ESQPMFMSNNVJSVCYKYTPH4.jpg)
/cloudfront-us-east-2.images.arcpublishing.com/reuters/OGBROYPEZVMVNLCKMBDIE2XJCE.jpg)
/cloudfront-us-east-2.images.arcpublishing.com/reuters/JG3AL7UAGVPBJHJUNQS4YZL4SE.jpg)
/cloudfront-us-east-2.images.arcpublishing.com/reuters/P23IVAPUQNLQVIQXRXEIPOU6ZA.jpg&description=Novartis%20initiates%20new%20trading%20line%20for%20share%20buybacks){kind=link}